RETAVASE
Drug
Chiesi USA, Inc.
Total Payments
$293,683
Transactions
287
Doctors
10
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $80,954 | 59 | 1 |
| 2022 | $104,428 | 113 | 3 |
| 2021 | $107,544 | 112 | 5 |
| 2019 | $757.17 | 3 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $290,662 | 274 | 99.0% |
| Consulting Fee | $2,100 | 1 | 0.7% |
| Travel and Lodging | $632.21 | 2 | 0.2% |
| Food and Beverage | $264.28 | 9 | 0.1% |
| Education | $24.20 | 1 | 0.0% |
Payments by Type
Research
$290,662
274 transactions
General
$3,021
13 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| READY-1 (CUSA-081) | CHIESI USA, INC. | $104,377 | 0 |
| Efficacy and Safety ofCUSA-081in the Restoration of Central Venous Access Device (CVAD) Functionality (READY1) | Chiesi USA, Inc. | $78,854 | 0 |
Top Doctors Receiving Payments for RETAVASE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Bethlehem, PA | $290,662 | 274 |
| , MD | Infectious Disease | Cary, NC | $2,100 | 1 |
| , MD | Cardiovascular Disease | Middleburg, FL | $757.17 | 3 |
| Laura Wilson | Acute Care | El Paso, TX | $41.33 | 2 |
| , MD | Internal Medicine | New Haven, CT | $20.73 | 1 |
| , M.D | Family Medicine | Jesup, GA | $20.72 | 1 |
| , MD | Internal Medicine | San Leandro, CA | $17.12 | 1 |
| , MD FACC FSCAI | Cardiovascular Disease | Fremont, CA | $17.11 | 1 |
| , M.D | Internal Medicine | Fremont, CA | $17.11 | 1 |
| , MD | Cardiovascular Disease | Philadelphia, PA | $15.70 | 1 |
| , M.D | Specialist | Angleton, TX | $13.70 | 1 |
Ad
Manufacturing Companies
- CHIESI USA, INC. $211,808
- Chiesi USA, Inc. $81,875
Product Information
- Type Drug
- Total Payments $293,683
- Total Doctors 10
- Transactions 287
About RETAVASE
RETAVASE is a drug associated with $293,683 in payments to 10 healthcare providers, recorded across 287 transactions in the CMS Open Payments database. The primary manufacturer is Chiesi USA, Inc..
Payment data is available from 2019 to 2023. In 2023, $80,954 was paid across 59 transactions to 1 doctors.
The most common payment nature for RETAVASE is "Unspecified" ($290,662, 99.0% of total).
RETAVASE is associated with 2 research studies, including "READY-1 (CUSA-081)" ($104,377).